Cytosorbents (CTSO) Cash from Investing Activities Growth (1y) (2011 - 2026)
Cytosorbents (CTSO) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | -15.64% |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | -514.42% |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | -87.14% |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | -73.71% |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | -12.26% |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | 618.55% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 48.43% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 91.33% |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | 0.00% |
| 10 | Cytosorbents | 21.41 Mn | 17.00 Mn | 7.05 Mn | 105.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 105.30% |
| Mar 31, 2026 | 2.13% |
| Dec 31, 2025 | -134.68% |
| Sep 30, 2025 | 118.39% |
| Jun 30, 2025 | -10.94% |
| Mar 31, 2025 | 63.00% |
| Dec 31, 2024 | 8.77% |
| Sep 30, 2024 | -16.02% |
| Jun 30, 2024 | -184.81% |
| Mar 31, 2024 | 81.40% |
| Dec 31, 2023 | 34.04% |
| Sep 30, 2023 | 64.03% |
| Jun 30, 2023 | 102.99% |
| Mar 31, 2023 | 19.47% |
| Dec 31, 2022 | 87.68% |
| Sep 30, 2022 | 29.58% |
| Jun 30, 2022 | -375.79% |
| Mar 31, 2022 | -39.85% |
| Dec 31, 2021 | -528.53% |
| Sep 30, 2021 | -151.75% |